Development and licensing agreement for TAG-72Development and Licensing Agreement • June 15th, 2021
Contract Type FiledJune 15th, 2021The agreement grants Enlyton exclusive worldwide rights to develop 3E8, a humanized monoclonal antibody (mAb) designed to target the tumor-associated glycoprotein 72 (TAG-72) antigen, for use in cancer detection and targeted drug delivery.